Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of BIBW 2992 in HER2-positive metastatic breast cancer after trastuzumab failure
2007-004805-80Phase 2Completed
- Start
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of afatinib in HER2-enriched breast cancer (HER2+). Primary endpoint: Objective response rate. Started Oct 2007; status: completed.
02
Drugs
afatinib
03
Conditions
HER2-enriched breast cancer (HER2+)
Beyond the preview
Go deeper on 2007-004805-80.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004805-80.